卡培他滨联合替雷利珠单抗治疗原发性皮肤鳞状细胞癌1例

doi:10.35541/cjd.20220606

Chinese Journal of Dermatology ›› 2025, e20220606.doi: 10.35541/cjd.20220606

• Case Reports • Previous Articles Next Articles

Capecitabine and tislelizumab for the treatment of primary cutaneous squamous cell carcinoma: a case report

Zhang Juanjuan¹, Wu Jun², Wang Yan¹, Zhu Mingfang²

¹Department of Dermatology, Liuyang Traditional Chinese Medicine Hospital, Liuyang 410300, Hunan, China; ²Department of Dermatology, the Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410005, China

Received:2022-08-25 Revised:2024-05-14 Online:2025-01-10 Published:2025-09-22
Contact: Zhu Mingfang E-mail:cszmf@126.com

Abstract

Zhang Juanjuan, Wu Jun, Wang Yan, Zhu Mingfang. Capecitabine and tislelizumab for the treatment of primary cutaneous squamous cell carcinoma: a case report[J]. Chinese Journal of Dermatology,2025,e20220606. doi:10.35541/cjd.20220606

References ［10］

［1］	Vu TT, Soong L, Hung T, et al. Cutaneous HPV16 and p16 positive basaloid squamous cell carcinoma with brain metastasis: a case report［J］. SAGE Open Med Case Rep, 2020,24（8）:2050313X20935260.doi:10.1177/ 2050313X20935260.
［2］	邹爱玲, 石年, 石娴, 等. p53及p16在皮肤鳞状细胞癌和鲍温病中的表达及意义［J］. 中国中西医结合皮肤性病学杂志, 2019,18（4）:293⁃298. doi: 10.3969/j.issn.1672⁃0709.2019.04. 002.
［3］	Corchado⁃Cobos R, García⁃Sancha N, González⁃Sarmiento R, et al. Cutaneous squamous cell carcinoma: from biology to therapy ［J］. Int J Mol Sci, 2020,21（8）:2956. doi: 10.3390/ijms21082956.
［4］	唐洪波, 马庆宇, 桑莹冰, 等. 紫外线和人乳头状瘤病毒16 E6协同诱导、促进裸鼠皮肤鳞状细胞癌的机制研究［J］. 中华皮肤科杂志, 2022,55（11）:982⁃989. doi: 10.35541/cjd.20220084.
［5］	Schauder DM, Kim J, Nijhawan RI. Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma: a systematic review ［J］. JAMA Dermatol, 2020,156（10）:1117⁃1124. doi: 10.1001/jamadermatol.2020.2327.
［6］	Manohar PM, Sapir E, Bellile E, et al. Capecitabine after surgical salvage in recurrent squamous cell carcinoma of head and neck ［J］. Otolaryngol Head Neck Surg, 2017,157（6）:995⁃997.doi: 10.1177/ 0194599817722948.
［7］	Weiss JM, Bagley S, Hwang WT, et al. Capecitabine and lapatinib for the first⁃line treatment of metastatic/recurrent head and neck squamous cell carcinoma ［J］. Cancer, 2016,122（15）:2350⁃2355. doi: 10.1002/cncr. 30067.
［8］	罗详冲, 王周清, 李琼艳, 等. PD⁃1抑制剂替雷利珠单抗治疗晚期恶性肿瘤的药理作用与临床评价［J］. 协和医学杂志, 2022,13（4）:679⁃686. doi: 10.12290/xhyxzz.2021⁃0691.
［9］	In GK, Vaidya P, Filkins A, et al. PD⁃1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California［J］. J Cancer Res Clin Oncol, 2021,147（6）:1803⁃1811. doi: 10.1007/s00432⁃020⁃03458⁃6.
［10］	Aboul⁃Fettouh N, Chen L, Ma J, et al. PD⁃1 inhibitors for cutaneous squamous cell carcinoma: a meta⁃analysis ［J］. Australas J Dermatol, 2022,63（1）:36⁃42. doi: 10.1111/ajd.13733.

Capecitabine and tislelizumab for the treatment of primary cutaneous squamous cell carcinoma: a case report

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［10］

Related Articles 0

Metrics

Comments

Recommended 10